Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions

Double Helix Consulting US (DHC US), headed by Andrew M. Baker, President, joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry as well as strong commercial, governmental and academic links, who provide customer-centric market access strategies to clients in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

• Product value message development and testing
• Commercial assessment
• Lifecycle planning
• Development program and clinical trial planning
• Managed markets strategy
• Pharmacoeconomic evaluation and health technology assessment (HTA)
• Payer and provider insight evaluation and influence planning
• Pricing and reimbursement strategy, negotiation simulation, and training
• Environmental scenario planning on key issues such as HTA decision intelligence, formulary design, utilization management strategies, policy reform, value-based benefit design, pay-for-performance, and healthcare quality measurement and accreditation
• Market access training

Speaking about the new business, Drew commented "Double Helix Consulting US offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client- and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies."

Based in the greater New York area, Double Helix Consulting US joins Double Helix Consulting's London office in providing market access services to clients around the world.

Drew Baker has over 20 years' experience operating in and consulting to the global biopharmaceutical and healthcare industries. He has led initiatives in commercial opportunity assessment, lifecycle management, strategic planning, global pricing and reimbursement, and value-based marketing. Before joining Double Helix, Drew spent 14 years with Pfizer and was a founding member of the company's Outcomes Research function. He also was with Merck's public policy group and spent six years in biopharmaceutical consulting. Drew has published and presented extensively in the areas of product value estimation, healthcare quality and health policy. He holds an MBA from Duke University, a Master of Public Affairs from Princeton, and a BA in economic policy and BS in communications from Syracuse University.

Commenting on the new venture, Dr Wayne Phillips, CEO of parent company Double Helix Group said "The establishment of Double Helix Consulting US is a further extension of our core business and continues our overall expansion and development program for 2009 and beyond."